Former MSD head of R&D Roger Perlmutter has continued the swift development track for cancer start-up Eikon Therapeutics, filing an IPO to build its already healthy cash position further. Eikon has ...
JPMorgan says weaker demand may cap gold gains near-term, sees rebound in late 2026 and 2027 JPMorgan ‌said on Thursday that softer buying from key demand sectors and gold's renewed sensitivity to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results